Lv71
4118 积分 2021-08-05 加入
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial
7天前
已完结
GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial
7天前
已完结
Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines
7天前
已完结
Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial
9天前
已关闭
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial
11天前
已完结
Multiple sclerosis: clinical aspects
13天前
已完结
Epidemiology and Pathophysiology of Multiple Sclerosis
13天前
已完结
Epidemiology and Clinical Manifestations of Immune Thrombocytopenia
14天前
已完结
Progress in APS pregnancy: Results from the IMPACT trial
14天前
已完结
Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial
17天前
已完结
皖公网安备34019202002308
